Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07123454 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1 study of B-Cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
91
Enrollment target
20
Study locations

NCT07123454 is a Phase 1 study of B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 91 participants, below the 126-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07123454, a Phase 1 study of B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
91 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).

Conditions Studied

B-Cell Non-Hodgkin Lymphoma

Interventions

  • DRUG AZD4512

Study Locations (20)

Other

  • Research Site - Melbourne
  • Research Site - Chengdu
  • Research Site - Guangzhou
  • Research Site - Bologna
  • Research Site - Milan
  • Research Site - Milan
  • Research Site - Bunkyō City
  • Research Site - Kōtoku
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Taichung
  • Research Site - Taipei
  • Research Site - London

New York

  • Research Site - New York
  • Research Site - New York

California

  • Research Site - Irvine

Florida

  • Research Site - Jacksonville

Minnesota

  • Research Site - Rochester

Ohio

  • Research Site - Cleveland

Tennessee

  • Research Site - Franklin

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2025-09-24
Est. Completion 2028-03-01
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07123454

The ClinicalTrials.gov registry entry for NCT07123454 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AZD4512 is the first listed.

NCT07123454 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, California.

Frequently Asked Questions

What is clinical trial NCT07123454 about?

NCT07123454 is a clinical study titled "A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).

What is the current status of trial NCT07123454?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2025-09-24. Estimated completion is 2028-03-01.

What conditions does trial NCT07123454 study?

This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT07123454?

The interventions under investigation include: AZD4512 (DRUG).

Who is sponsoring clinical trial NCT07123454?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07123454 being conducted?

This trial has 20 study locations across California, Florida, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-Cell Non-Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.